Top

Published in:

01-02-2010 | Preclinical study

A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks

Authors: L. J. Lancashire, D. G. Powe, J. S. Reis-Filho, E. Rakha, C. Lemetre, B. Weigelt, T. M. Abdel-Fatah, A. R. Green, R. Mukta, R. Blamey, E. C. Paish, R. C. Rees, I. O. Ellis, G. R. Ball

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Abstract

Gene expression microarrays allow for the high throughput analysis of huge numbers of gene transcripts and this technology has been widely applied to the molecular and biological classification of cancer patients and in predicting clinical outcome. A potential handicap of such data intensive molecular technologies is the translation to clinical application in routine practice. In using an artificial neural network bioinformatic approach, we have reduced a 70 gene signature to just 9 genes capable of accurately predicting distant metastases in the original dataset. Upon validation in a follow-up cohort, this signature was an independent predictor of metastases free and overall survival in the presence of the 70 gene signature and other factors. Interestingly, the ANN signature and CA9 expression also split the groups defined by the 70 gene signature into prognostically distinct groups. Subsequently, the presence of protein for the principal prognosticator gene was categorically assessed in breast cancer tissue of an experimental and independent validation patient cohort, using immunohistochemistry. Importantly our principal prognosticator, CA9, showed that it is capable of selecting an aggressive subgroup of patients who are known to have poor prognosis.

Available only for authorised users

Brown PO, Botstein D (1999) Exploring the new world of the genome with DNA microarrays. Nat Genet 21((1)(Suppl)):33–37. doi:10.1038/4462 CrossRefPubMed

Bhattacharjee A, Richards WG, Staunton J et al (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98(24):13790–13795. doi:10.1073/pnas.191502998 CrossRefPubMed

Khan J, Wei JS, Ringner M et al (2001) Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 7(6):673–679. doi:10.1038/89044 CrossRefPubMed

Rosenwald A, Wright G, Chan WC et al (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346(25):1937–1947. doi:10.1056/NEJMoa012914 CrossRefPubMed

Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874. doi:10.1073/pnas.191367098 CrossRefPubMed

West M, Blanchette C, Dressman H et al (2001) Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 98(20):11462–11467. doi:10.1073/pnas.201162998 CrossRefPubMed

Callagy G, Cattaneo E, Daigo Y et al (2003) Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 12(1):27–34. doi:10.1097/00019606-200303000-00004 CrossRefPubMed

Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. doi:10.1056/NEJMoa041588 CrossRefPubMed

Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. doi:10.1038/35021093 CrossRefPubMed

10.

Abd El-Rehim DM, Ball G, Pinder SE et al (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3):340–350. doi:10.1002/ijc.21004 CrossRefPubMed

11.

Masters JR, Lakhani SR (2000) How diagnosis with microarrays can help cancer patients. Nature 404(6781):921. doi:10.1038/35010139 CrossRefPubMed

12.

Naderi A, Teschendorff AE, Barbosa-Morais NL et al (2007) A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene 26(10):1507–1516. doi:10.1038/sj.onc.1209920 CrossRefPubMed

13.

van ‘t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536. doi:10.1038/415530a CrossRef

14.

Fan C, Oh DS, Wessels L et al (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355(6):560–569. doi:10.1056/NEJMoa052933 CrossRefPubMed

15.

Wirapati P, Sotiriou C, Kunkel S et al (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10(4):R65. doi:10.1186/bcr2124 CrossRefPubMed

16.

Lancashire LJ, Rees RC, Ball GR (2008) Identification of gene transcript signatures predictive for estrogen receptor and lymph node status using a stepwise forward selection artificial neural network modelling approach. Artif Intell Med 43(2):99–111. doi:10.1016/j.artmed.2008.03.001 CrossRefPubMed

17.

Ball G, Mian S, Holding F et al (2002) An integrated approach utilizing artificial neural networks and SELDI mass spectrometry for the classification of human tumours and rapid identification of potential biomarkers. Bioinformatics 18(3):395–404. doi:10.1093/bioinformatics/18.3.395 CrossRefPubMed

18.

Lancashire L, Schmid O, Shah H et al (2005) Classification of bacterial species from proteomic data using combinatorial approaches incorporating artificial neural networks, cluster analysis and principal components analysis. Bioinformatics 21(10):2191–2199. doi:10.1093/bioinformatics/bti368 CrossRefPubMed

19.

Matharoo-Ball B, Ball G, Rees R (2007) Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches—a prostate cancer perspective. Vaccine 25(Suppl 2):B110–B121CrossRefPubMed

20.

van de Vijver MJ, He YD, van ‘t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999–2009. doi:10.1056/NEJMoa021967 CrossRefPubMed

21.

Rumelhart DE, Hinton GE, Williams RJ (1986) Learning representations by back-propagating errors. Nature 323:533–536CrossRef

22.

Picard RR, Cook RD (1984) Cross-validation of regression models. J Am Stat Assoc 79(387):575–583CrossRef

23.

Xu QS, Liang YZ, Du YP (2004) Monte Carlo cross-validation for selecting a model and estimating the prediction error in multivariate calibration. J Chemometr 18(2):112–120. doi:10.1002/cem.858 CrossRef

24.

Shao J (1993) Linear model selection by cross-validation. J Am Stat Assoc 88(422):486–494. doi:10.2307/2290328 CrossRef

25.

Efron B (1986) How biased is the apparent error rate of a prediction rule? J Am Stat Assoc 81(394):461–470. doi:10.2307/2289236 CrossRef

26.

Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11(3):359–377PubMed

27.

Colpaert CG, Vermeulen PB, Fox SB et al (2004) The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. Breast Cancer Res Treat 81(2):137–147. doi:10.1023/A:1025702330207 CrossRef

28.

Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374. doi:10.1158/1078-0432.CCR-04-0220 CrossRefPubMed

29.

Raghunand N, He X, van Sluis R et al (1999) Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 80(7):1005–1011. doi:10.1038/sj.bjc.6690455 CrossRefPubMed

30.

van Berkel M, van der Groep P, Schvarts A et al (2002) HIF-1alpha/CAIX coexpression in invasive human breast cancer. Breast Cancer Res Treat 76(Suppl 1):S146

31.

Saarnio J, Parkkila S, Parkkila AK et al (1998) Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 153(1):279–285PubMed

32.

Liao SY, Brewer C, Zavada J et al (1994) Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 145(3):598–609PubMed

33.

Hockel M, Schlenger K, Aral B et al (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56(19):4509–4515PubMed

34.

Brizel DM, Scully SP, Harrelson JM et al (1996) Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56(5):941–943PubMed

35.

Brennan DJ, Jirstrom K, Kronblad A et al (2006) CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res 12(21):6421–6431. doi:10.1158/1078-0432.CCR-06-0480 CrossRefPubMed

36.

Chia SK, Wykoff CC, Watson PH et al (2001) Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol 19(16):3660–3668PubMed

37.

Tomes L, Emberley E, Niu Y et al (2003) Necrosis and hypoxia in invasive breast carcinoma. Breast Cancer Res Treat 81(1):61–69. doi:10.1023/A:1025476722493 CrossRefPubMed

38.

Trastour C, Benizri E, Ettore F et al (2007) HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer 120(7):1451–1458. doi:10.1002/ijc.22436 CrossRefPubMed

39.

Kronblad A, Hedenfalk I, Nilsson E et al (2005) ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells. Oncogene 24(45):6835–6841. doi:10.1038/sj.onc.1208830 CrossRefPubMed

40.

Storci G, Sansone P, Trere D et al (2008) The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J Pathol 214(1):25–37. doi:10.1002/path.2254 CrossRefPubMed

41.

Fadare O, Tavassoli FA (2007) The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol 14(5):358–373. doi:10.1097/PAP.0b013e31814b26fe CrossRefPubMed

42.

Van den Eynden GG, Smid M, Van Laere SJ et al (2008) Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer. Clin Cancer Res 14(10):2944–2952. doi:10.1158/1078-0432.CCR-07-4397 CrossRefPubMed

43.

Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368–1376. doi:10.1158/1078-0432.CCR-07-1658 CrossRefPubMed

44.

Turner NC, Reis-Filho JS (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25(43):5846–5853. doi:10.1038/sj.onc.1209876 CrossRefPubMed

45.

Vleugel MM, Greijer AE, Shvarts A et al (2005) Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 58(2):172–177. doi:10.1136/jcp.2004.019885 CrossRefPubMed

46.

Gery S, Sawyers CL, Agus DB et al (2002) TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene 21(31):4739–4746. doi:10.1038/sj.onc.1205142 CrossRefPubMed

47.

Gery S, Koeffler HP (2003) Repression of the TMEFF2 promoter by c-Myc. J Mol Biol 328(5):977–983. doi:10.1016/S0022-2836(03)00404-2 CrossRefPubMed

48.

Glinsky GV, Berezovska O, Glinskii AB (2005) Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 115(6):1503–1521. doi:10.1172/JCI23412 CrossRefPubMed

49.

Hayama S, Daigo Y, Kato T et al (2006) Activation of CDCA1-KNTC2, members of centromere protein complex, involved in pulmonary carcinogenesis. Cancer Res 66(21):10339–10348. doi:10.1158/0008-5472.CAN-06-2137 CrossRefPubMed

50.

Gurzov EN, Izquierdo M (2006) RNA interference against Hec1 inhibits tumor growth in vivo. Gene Ther 13(1):1–7. doi:10.1038/sj.gt.3302595 CrossRefPubMed

Title: A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks
Authors: L. J. Lancashire
D. G. Powe
J. S. Reis-Filho
E. Rakha
C. Lemetre
B. Weigelt
T. M. Abdel-Fatah
A. R. Green
R. Mukta
R. Blamey
E. C. Paish
R. C. Rees
I. O. Ellis
G. R. Ball
Publication date: 01-02-2010
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-009-0378-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

Role of endothelial progenitor cells in breast cancer angiogenesis: from fundamental research to clinical ramifications

Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study

A novel germline CHEK2 deletion truncating the kinase domain identified in a French family with high-risk of breast/ovarian cancer

Low level alcohol intake, cigarette smoking and risk of breast cancer in Asian-American women

Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis

Evaluation of malignancy-risk gene signature in breast cancer patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer